Food and Drug Administration (FDA) Commissioner Scott Gottlieb said on Tuesday that tobacco giant Altria went back on its promise to clamp down on vape pods with its $12.8 billion investment in e-cigarette decacorn Juul Labs.
Food and Drug Administration Commissioner Scott Gottlieb said on Tuesday that tobacco giant Altria went back on its promise to clamp down on vape pods with its $12.8 billion investment in e-cigarette decacorn Juul Labs.
‘I assume it’s just a business decision’Gottlieb explained that he had asked the e-cigarette industry for a plan to address the teen vaping epidemic in October last year. Altria then withdrew some of its brands, like MarkTen and Green Smoke. But around the same time, it made the investment in the top performer in the market — Juul.
He added: “I assume it’s just a business decision they made to withdraw a product that didn’t have good market penetration and go on to make an investment in a similar product that did have the market penetration.” “We do see evidence now that adult smokers are transitioning” from traditional tobacco products with the help of e-cigarettes, Gottlieb acknowledged. “But it cannot come at the expense of the youth we’re seeing.”
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Altria shares fall after FDA's Gottlieb describes 'difficult' meeting on Juul
Consulte Mais informação »
FDA considers yanking nicotine vaping pods off the marketU.S. Food and Drug Administration Commissioner Scott Gottlieb said Tuesday that his agency may need to pull pod-based nicotine products off the market as it fights a surge in teen vaping.
Consulte Mais informação »
FDA's departing chief considers yanking nicotine vaping pods off the marketOutgoing FDA Commissioner Scott Gottlieb said he had a “difficult” meeting with Juul and Altria as his agency fights a surge in vaping by teenagers.
Consulte Mais informação »
Buy these tobacco stocks for smokin’ profitsLook at Altria, Philip Morris International and Turning Point Brands.
Consulte Mais informação »
FDA puts partial hold on clinical trials of AbbVie's cancer drugAbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partia...
Consulte Mais informação »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Consulte Mais informação »
J&J and Sientra get FDA warning letters for breast implantsThe U.S. Food and Drug Administration has issued warning letters to Sientra Inc ...
Consulte Mais informação »
Sage stock rises after FDA approves first postpartum depression treatment Zulresso
Consulte Mais informação »